- Email: [email protected]
Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
Annals of Oncology 25 (Supplement 5): v44–v74, 2014 doi:10.1093/annonc/mdu435.103
Oral Session (Oral presentations categorized by each organ) O3
4
1
EXPRESSION AND CLINICAL SIGNIFICANCE OF ANDROGEN RECEPTOR IN TRIPLE-NEGATIVE BREAST CANCER
abstracts
Yuka Asano1, Shinichiro Kashiwagi1, Kento Kurata1, Tamami Morisaki1, Satoru Noda1, Hidemi Kawajiri1, Tsutomu Takashima1, Naoyoshi Onoda1, Masahiko Ohsawa2, Kosei Hirakawa1 1 Department of Surgical Oncology, Osaka City University Graduate School of Medicine 2 Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine
Background: Triple-negative breast cancer (TNBC), a subtype of breast tumor with ER negative, PR negative, and HER2 negative, shows a poor prognosis because of a frequent recurrence. Androgen receptor (AR) is involved in the pathogenesis of breast cancer, but its role is not clearly defined. This study was to explore the expression of AR and its relationship with clinicopathologic parameters in TNBC. Methods: This study investigated a consecutive series of 1036 cases of sporadic invasive breast carcinoma. Immunohistological assays were performed to determine the expression of AR in 190 of TNBC. The relationships between AR expression and clinicopathologic data and prognosis were analyzed. Results: Of informative 1036 breast cancer cases, triple-negative phenotype was 190 (18.3%). TNBC patients experienced a poorer prognosis in comparison to non-TNBC patients ( p < 0.001, log-rank). The cases with AR expression was found in 56 patients (29.5%) in TNBC. In 190 TNBC cases, the prognosis of AR-negative patients was significantly poor ( p = 0.019, log-rank), and it was an independent indicator of a poor prognosis by multivariate analyses ( p = 0.039). Conclusions: AR might be a prognostic marker and possible endocrine target for therapy in patients with TNBC.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]. Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v69/2240207/O3-4-1EXPRESSION-AND-CLINICAL-SIGNIFICANCE-OF by guest on 05 September 2017
Oral Session (Oral presentations categorized by each organ) O3
4
1
EXPRESSION AND CLINICAL SIGNIFICANCE OF ANDROGEN RECEPTOR IN TRIPLE-NEGATIVE BREAST CANCER
abstracts
Yuka Asano1, Shinichiro Kashiwagi1, Kento Kurata1, Tamami Morisaki1, Satoru Noda1, Hidemi Kawajiri1, Tsutomu Takashima1, Naoyoshi Onoda1, Masahiko Ohsawa2, Kosei Hirakawa1 1 Department of Surgical Oncology, Osaka City University Graduate School of Medicine 2 Deaprtment of Diagnostic Pathology, Osaka City University Graduate School of Medicine
Background: Triple-negative breast cancer (TNBC), a subtype of breast tumor with ER negative, PR negative, and HER2 negative, shows a poor prognosis because of a frequent recurrence. Androgen receptor (AR) is involved in the pathogenesis of breast cancer, but its role is not clearly defined. This study was to explore the expression of AR and its relationship with clinicopathologic parameters in TNBC. Methods: This study investigated a consecutive series of 1036 cases of sporadic invasive breast carcinoma. Immunohistological assays were performed to determine the expression of AR in 190 of TNBC. The relationships between AR expression and clinicopathologic data and prognosis were analyzed. Results: Of informative 1036 breast cancer cases, triple-negative phenotype was 190 (18.3%). TNBC patients experienced a poorer prognosis in comparison to non-TNBC patients ( p < 0.001, log-rank). The cases with AR expression was found in 56 patients (29.5%) in TNBC. In 190 TNBC cases, the prognosis of AR-negative patients was significantly poor ( p = 0.019, log-rank), and it was an independent indicator of a poor prognosis by multivariate analyses ( p = 0.039). Conclusions: AR might be a prognostic marker and possible endocrine target for therapy in patients with TNBC.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]. Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v69/2240207/O3-4-1EXPRESSION-AND-CLINICAL-SIGNIFICANCE-OF by guest on 05 September 2017